Evidence map›Paper›PMID 38696215›Full record

ArticleThe journal of physical chemistry. B2024

In Bacterial Membranes Lipid II Changes the Stability of Pores Formed by the Antimicrobial Peptide Nisin.

Miranda S Sheridan, Preeti Pandey, Ulrich H E Hansmann

Open access · greenAbstract read
In one paragraph

Article in The journal of physical chemistry. B, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Miranda S SheridanDepartment of Chemistry & Biochemistry, University of Oklahoma, Norman, Oklahoma 73019, United States.
Preeti PandeyDepartment of Physics and Astronomy, Clemson University, Clemson, South Carolina 29634, United States.
Ulrich H E HansmannDepartment of Chemistry & Biochemistry, University of Oklahoma, Norman, Oklahoma 73019, United States.ORCID 0000-0002-0700-4835
University of Oklahoma · USClemson University · US

Funding

Efficient and Accurate Force Fields for Computer-Aided Drug DesignR01GM120578 · NIGMS · UNIVERSITY OF ARKANSAS AT FAYETTEVILLE · PI Feng Wang · 2017 to 2026
$1.9M
NIGMS NIH HHS R01 GM120578
6 · The paper itself

Abstract

Resistance to available antibiotics poses a growing challenge to modern medicine, as this often disallows infections to be controlled. This problem can only be alleviated by the development of new drugs. Nisin, a natural lantibiotic with broad antimicrobial activity, has shown promise as a potential candidate for combating antibiotic-resistant bacteria. However, nisin is poorly soluble and barely stable at physiological pH, which despite attempts to address these issues through mutant design has restricted its use as an antibacterial drug. Therefore, gaining a deeper understanding of the antimicrobial effectiveness, which relies in part on its ability to form pores, is crucial for finding innovative ways to manage infections caused by resistant bacteria. Using large-scale molecular dynamics simulations, we find that the bacterial membrane-specific lipid II increases the stability of pores formed by nisin and that the interplay of nisin and lipid II reduces the overall integrity of bacterial membranes by changing the local thickness and viscosity.

Indexed as

Molecular Dynamics SimulationNisinUridine Diphosphate N-Acetylmuramic AcidAnti-Bacterial AgentsCell MembraneAnti-Bacterial Agentsmuramyl-NAc-(pentapeptide)pyrophosphoryl-undecaprenolNisinUridine Diphosphate N-Acetylmuramic Acid

Identifiers

PMID38696215
PMCPMC11104519
OpenAlexW4396577018

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.